Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021
Abstracts are now available online within Nephrology Dialysis Transplantation (NDT), the official journal for the ERA-EDTA.
Akebia-sponsored mini-oral sessions are:
- Hematologic Efficacy of Vadadustat for Anemia in Patients with Kidney Failure on Dialysis (Presentation ID: MO539)
- Hematologic Efficacy of Vadadustat for Anemia in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (Presentation ID: MO541)
For more information on
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. Vadadustat is not approved by the
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-presentations-at-era-edta-virtual-congress-2021-301304979.html